Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.7%

8 terminated/withdrawn out of 216 trials

Success Rate

91.1%

+4.6% vs industry average

Late-Stage Pipeline

6%

14 trials in Phase 3/4

Results Transparency

4%

3 of 82 completed trials have results

Key Signals

42 recruiting3 with results6 terminated

Enrollment Performance

Analytics

Phase 2
74(52.9%)
N/A
46(32.9%)
Phase 3
11(7.9%)
Phase 1
5(3.6%)
Phase 4
3(2.1%)
Early Phase 1
1(0.7%)
140Total
Phase 2(74)
N/A(46)
Phase 3(11)
Phase 1(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (216)

Showing 20 of 216 trials
NCT06629896Not ApplicableRecruiting

Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomized Controlled Trial

Role: collaborator

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT07507578Recruiting

A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma

Role: lead

NCT06680401Recruiting

Epithelioid Haemangioendothelioma Observational Study

Role: lead

NCT05315570Not ApplicableCompleted

Big Data for Quality of Life in Head and Neck Cancer

Role: lead

NCT06320184Active Not Recruiting

AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs

Role: lead

NCT07496242Recruiting

Immunological Phenotype of Desmoid-fibromatosis-affected Patients.

Role: lead

NCT03654105Phase 2Active Not Recruiting

Screening and Multiple Intervention on Lung Epidemics

Role: lead

NCT07461246Active Not Recruiting

Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)

Role: lead

NCT07428018Phase 2Not Yet Recruiting

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Role: collaborator

NCT03057106Phase 2Active Not Recruiting

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Role: collaborator

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Role: collaborator

NCT04794127Phase 2Completed

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

Role: collaborator

NCT05289739Not ApplicableCompleted

Exercise Training in Childhood Cancer

Role: collaborator

NCT07372261Enrolling By Invitation

Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer

Role: collaborator

NCT04689347Phase 1Recruiting

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Role: lead

NCT07265661Not ApplicableNot Yet Recruiting

Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma

Role: collaborator

NCT06799624Not Yet Recruiting

Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr

Role: lead

NCT04765709Phase 2Terminated

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Role: collaborator

NCT07253402Recruiting

Microbiota-guided Radiotherapy for Head and Neck Cancer

Role: lead